Want to see AU:VBS full AI Analyst Report?
Top Page
Vectus Biosystems Limited
(Sydney:VBS)
Select Model
Select Model
Rating:54Neutral
Price Target:
AU$0.19
â–˛(5.00% Upside)
Action:Reiterated
Date:09/06/26
The score is held back primarily by weak financial performance: zero revenue in 2026, ongoing operating losses, and persistent negative operating/free cash flow. Offsetting this are improving balance-sheet metrics (positive equity and moderate leverage) and supportive technical momentum, with valuation appearing low on P/E but less convincing given the weak operating and cash-flow profile.
Positive Factors
High gross margins
A consistently very high gross margin profile provides durable unit economics: once revenue stabilizes, gross profits can cover fixed R&D and G&A. Over the medium term this supports scalable margin expansion and gives management leverage to prioritize profitable product lines or partnerships.
Negative Factors
Shrinking revenue
A 45.9% revenue decline is a structural red flag: it erodes scale, weakens pricing leverage, and increases per-unit fixed cost absorption. Over several quarters this trend materially lengthens the path to breakeven, undermines investor confidence, and raises the likelihood of repeated capital raises.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margins
A consistently very high gross margin profile provides durable unit economics: once revenue stabilizes, gross profits can cover fixed R&D and G&A. Over the medium term this supports scalable margin expansion and gives management leverage to prioritize profitable product lines or partnerships.
Read all positive factors
Vectus Biosystems Limited (VBS) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$11.50M
Dividend YieldN/A
Average Volume (3M)6.52K
Price to Earnings (P/E)6.4
Beta (1Y)1.14
Revenue GrowthN/A
EPS GrowthN/A
CountryAU
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.03
Shares Outstanding62,183,052
10 Day Avg. Volume6,849
30 Day Avg. Volume6,516
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)2.92
Price to Sales (P/S)0.00
P/FCF Ratio-11.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Vectus Biosystems Limited Business Overview & Revenue Model
Company Description
Vectus Biosystems Limited, an Australian medical research and development firm, specializes in devising therapies for fibrotic conditions and hypertension. Its pharmaceutical pipeline addresses ailments affecting the heart, kidneys, liver, and lun...
How the Company Makes Money
null...
Vectus Biosystems Limited Financial Statement Overview
Summary
Income Statement
26
Negative
Balance Sheet
48
Neutral
Cash Flow
22
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 478.18K | 1.14M | 1.35M | 1.30M |
| Gross Profit | -4.60K | 478.18K | 1.14M | 1.31M | 1.28M |
| EBITDA | -1.36M | -1.69M | -2.27M | -3.19M | -3.28M |
| Net Income | 1.56M | -1.78M | -2.34M | -3.45M | -3.99M |
Balance Sheet | |||||
| Total Assets | 3.82M | 782.66K | 2.03M | 4.63M | 3.94M |
| Cash, Cash Equivalents and Short-Term Investments | 3.52M | 250.99K | 808.97K | 2.95M | 1.28M |
| Total Debt | 546.66K | 200.00K | 28.93K | 70.21K | 6.90M |
| Total Liabilities | 1.50M | 1.04M | 539.26K | 1.11M | 8.36M |
| Stockholders Equity | 2.32M | -256.62K | 1.49M | 3.52M | -4.42M |
Cash Flow | |||||
| Free Cash Flow | -573.40K | -830.09K | -2.10M | -2.37M | -4.46M |
| Operating Cash Flow | -573.39K | -830.09K | -2.03M | -2.35M | -4.44M |
| Investing Cash Flow | 0.00 | 101.03K | -67.90K | -17.13K | -21.00K |
| Financing Cash Flow | 1.04M | 171.07K | -41.28K | 4.04M | -34.55K |
Vectus Biosystems Limited Technical Analysis
Positive
0.18
Price Trends
0.16
Positive
0.14
Positive
0.14
Positive
Market Momentum
<0.01
Negative
65.48
Neutral
66.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:VBS, the sentiment is Positive. The current price of 0.18 is above the 20-day moving average (MA) of 0.17, above the 50-day MA of 0.16, and above the 200-day MA of 0.14, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 65.48 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:VBS.
Vectus Biosystems Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | AU$11.50M | 6.42 | 206.11% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$13.54M | -2.74 | -164.96% | ― | -4.24% | 33.39% | |
49 Neutral | AU$196.08M | -13.58 | -36.83% | ― | 51.07% | -47.63% | |
47 Neutral | AU$57.47M | -0.65 | -118.74% | ― | 499.47% | 31.20% | |
46 Neutral | AU$6.67M | -7.86 | -45.29% | 9.09% | 290.25% | 92.05% | |
43 Neutral | AU$5.44M | -1.02 | -52.04% | ― | 32.22% | -26.53% |
* Healthcare Sector Average
AU:VBS
Vectus Biosystems Limited
0.19
0.11
153.42%
AU:ACR
Acrux
0.01
>-0.01
-21.43%
AU:OCC
Orthocell Ltd
0.72
-0.47
-39.50%
AU:TRP
Tissue Repair Ltd
0.09
-0.19
-67.86%
AU:CMB
Regeneus Ltd.
0.46
-0.05
-10.68%
AU:BOT
Botanix Pharmaceuticals Limited
0.02
-0.12
-85.00%
Vectus Biosystems Limited Corporate Events
Vectus Biosystems Director Converts Options into Shares, Boosting Equity Stake
Sep 4, 2026
Vectus Biosystems Limited has reported a change in director Maurie Stang’s interests, with the exercise of 316,000 zero-priced options into fully paid ordinary shares. Following this transaction on 2 September 2026, Stang’s holdings no...
Vectus Biosystems Issues New Shares to Non-Executive Director Under Incentive Plan
Sep 2, 2026
Vectus Biosystems Limited has issued 316,000 new fully paid ordinary shares to Deputy Chairman and Non-Executive Director Maurie Stang, following the exercise of options granted under the company’s Employee Incentive Plan as payment for dire...
Vectus Biosystems Seeks ASX Quotation for 316,000 New Shares
Sep 2, 2026
Vectus Biosystems Limited has applied for quotation on the ASX of 316,000 new ordinary fully paid shares under its existing ticker VBS. The securities, issued on September 2, 2026, arise from the exercise or conversion of options or other converti...
Vectus Biosystems Sharpens Strategy as VB0004 Takes Centre Stage
Aug 30, 2026
Vectus Biosystems has entered a new phase of development in 2025-26, appointing Dr Tara Speranza as chief executive and chief technology officer to sharpen its drug development and commercial strategy. Her appointment is intended to strengthen int...
Vectus Biosystems Swings to Profit as Revenue Soars and Balance Sheet Strengthens
Aug 30, 2026
Vectus Biosystems Limited reported a sharp turnaround for the year to 30 June 2026, with revenues from ordinary activities surging 478.7% to $2.77 million and a consolidated profit after tax of $1.56 million, compared with a restated loss of $1.86...
Vectus Biosystems Issues New Shares Under Employee Incentive Plan
Jul 29, 2026
Vectus Biosystems has issued 176,703 new fully paid ordinary shares following the exercise of employee options under its incentive plan. The bulk of the allocation, 163,500 shares, went to Chief Executive Officer and Chief Technology Officer Dr Ta...
Vectus Biosystems Seeks ASX Quotation for Additional Ordinary Shares
Jul 29, 2026
Vectus Biosystems Limited has applied for the quotation of 176,703 new ordinary fully paid shares on the ASX, with an issue date of July 29, 2026. The additional securities, arising from the exercise or conversion of existing instruments, will mod...
Vectus Biosystems bolsters leadership, funding and U.S. regulatory push for fibrosis pipeline
Jul 28, 2026
Vectus Biosystems has strengthened its leadership by appointing Dr Tara Speranza as Chief Executive Officer and Chief Technology Officer, leveraging her extensive experience in scientific research, drug development and capital markets to support t...
Vectus Biosystems Appoints U.S. Regulatory Agent to Advance IPF Drug VB0004
Jul 13, 2026
Vectus Biosystems has appointed Cardinal Health Regulatory Services as its U.S. Regulatory Agent to manage all Food and Drug Administration interactions for its lead compound, VB0004, including orphan drug designation, pre-IND discussions and the ...
Vectus Biosystems issues new shares to CEO under incentive plan
Jun 26, 2026
Vectus Biosystems Limited has issued 196,200 new fully paid ordinary shares to its Chief Executive Officer and Chief Technology Officer, Dr Tara Speranza, following the exercise of options granted under the company’s Employee Incentive Plan ...
Vectus Biosystems Lists Additional Shares on ASX
Jun 26, 2026
Vectus Biosystems Limited has applied for the quotation of 196,200 new ordinary fully paid shares on the Australian Securities Exchange, with an issue date of 26 June 2026. The additional securities, arising from exercised options or converted ins...
Vectus Biosystems’ New CEO to Outline Antifibrotic Strategy in Investor Webinar
Jun 16, 2026
Vectus Biosystems will host an investor webinar on 23 June 2026, led by newly appointed CEO and CTO Dr Tara Speranza, to outline the company’s refreshed strategic direction and near-term priorities. The session will cover plans to advance it...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.